gpt-dict.com

植物固醇 Phytosterols × 良性攝護腺肥大

結論：證據支持但有警示

本評估限定於 beta-sitosterol（植物固醇中與攝護腺相關的成分）用於改善良性攝護腺肥大（BPH）下泌尿道症狀。

C 🟠 C 薄弱證據 附警語發布 🚨 high — heavy affiliate marketing in TW community
⚠️ 標記 ⚠️ stale 🇹🇼 台灣在地警示 💊 檢驗 / 藥物交互作用

本評估限定於 beta-sitosterol（植物固醇中與攝護腺相關的成分）用於改善良性攝護腺肥大（BPH）下泌尿道症狀。

最強的證據是 2000 年 Cochrane 系統性回顧（Wilt，4 篇雙盲 RCT、519 人）與兩項中等品質 RCT（Berges 1995、Klippel 1997），方向一致顯示能改善排尿症狀分數（IPSS WMD -4.9 分）、尖峰尿流速與殘餘尿量。

然而證據基礎存在三項硬傷：（1）所有試驗皆無法縮小攝護腺體積，僅是症狀緩解；（2）試驗多為 1995-2000 年、療程 ≤26 週，缺長期療效、安全與併發症預防數據，且以德國 Harzol 製劑為主、萃取方法異質、贊助來源未揭露；（3）監管與學會層級不支持——AUA BPH/LUTS 指引將植物療法歸為「新興療法、因證據不足不建議使用」，FDA／TFDA 的植物固醇核可宣稱僅限降膽固醇、完全未涉及 BPH，NIH ODS／NCCIH 亦未評估。

L2 證據雖一致但屬過時、體積中等、可能有產業偏倚的初步資料，配合學會明確不推薦，獨立評定為 C（薄弱證據），而非 B。

⚖️

評分透明度

所有分數由 7 層證據引擎計算，過程公開可查
原始分數 0.52
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 附警語發布
信心度
79%
證據方向大致一致
證據層級
E1
Cochrane 高品質系統性回顧／統合分析

各層「支持此療效」的程度

分數越低＝該層越不支持
L5 臨床機構權威立場
0.34
L1 Examine國際基準
0.50
L11 AI 複核獨立判讀
0.50
L2 PubMed原始文獻
0.70
L3 機轉生理合理性
0.75
不支持 中性 / 混合 支持
▸查看完整決策路徑（audit trail）
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.523
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Beta-sitosterols for benign prostatic hyperplasia
PMID: 10796740 2000 Cochrane SR n = 519
結論：Pooled analysis of 4 placebo-controlled double-blind RCTs (519 men, 4-26 weeks) found non-glucosidic beta-sitosterols significantly improved symptom scores (IPSS WMD -4.9, 95% CI -6.3 to -3.5, n=2 studies), peak urine flow (WMD +3.91 mL/s, 95% CI 0.91 to 6.90, n=4) and residual volume (WMD -28.62 mL, 95% CI -41.42 to -15.83, n=4); no reduction in prostate size, and withdrawal rates were comparable to placebo (7.8% vs 8.0%).
🟢 高品質 效應量：[object Object]
前往 PubMed
Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia
PMID: 7540705 1995 RCT (double-blind) n = 200
結論：In 200 men with symptomatic BPH (Berges/German Beta-sitosterol Study Group, 8 centres), the modified Boyarsky score fell by a mean of -6.7 points with beta-sitosterol versus -2.1 with placebo; IPSS, peak urinary flow and mean residual volume also improved significantly versus placebo, while prostate volume was unchanged.
效應量：[object Object]
前往 PubMed
A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of BPH
PMID: 9313662 1997 RCT (double-blind) n = 177
結論：In 177 men across 13 centres (German BPH-Phyto Study Group, Klippel et al.), 130 mg/day beta-sitosterol produced a significant placebo-adjusted IPSS improvement of 5.4 points (P<0.01) and a 0.9-point quality-of-life improvement; secondary outcomes also improved, with Qmax +4.5 mL/s and PVR -33.5 mL versus placebo.
效應量：[object Object]
前往 PubMed
Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up
PMID: 10792163 2000 Cohort n = 117
結論：Open-label follow-up of the Berges RCT cohort re-evaluated 117 of 200 patients (59%) at 18 months; men who continued beta-sitosterol largely maintained the symptom and flow improvements gained in the first 6 months, while the 41 patients choosing no further therapy showed slightly worse symptom scores and PVR but unchanged Qmax.
🟠 品質有限
前往 PubMed

L4a US FDA
支持
Foods containing at least 0.65 g per serving of plant sterol esters, eaten twice a day with meals for a daily total intake of at least 1.3 g, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease. 來源↗
L4b EU EFSA
支持
L4c UK NHS
反對
Do not advise any of the following to take plant stanols or sterols to prevent CVD: people being treated for primary prevention; people being treated for secondary prevention; people with CKD; people with type 1 diabetes; people with type 2 diabetes. [2014] 來源↗
L4d TW TFDA / 衛福部
支持
市售有兩款添加植醇的植物油（透過衛福部審核通過之健康食品資料庫）。每日攝取2到3克的植物固醇，對於降低血中的總膽固醇與低密度脂蛋白膽固醇（壞的膽固醇）都有顯著的幫助。 來源↗
L4e WHO
中性
JECFA established a group acceptable daily intake (ADI) of 0-40 mg/kg body weight for phytosterols, phytostanols and their esters, expressed as the sum of phytosterols and phytostanols in their free form, based on an overall NOAEL of 4200 mg/kg bw per day to which a safety factor of 100 was applied. 來源↗

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
謹慎
L5d Harvard Health
中性
L5e Specialty Society (condition-mapped)
反對

PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽

台灣社群討論攝護腺肥大幾乎都圍繞鋸棕櫚、南瓜籽油、茄紅素、鋅複方，少有人單獨討論「植物固醇/β-sitosterol」本身；植物固醇多以複方成分被埋沒提及，缺乏針對性實測心得。

💬社群實感

無共識（社群幾乎不單獨討論植物固醇用於攝護腺肥大，多以鋸棕櫚/南瓜籽油複方形式被提及，無針對性實測心得）

破解迷思 社群最常見的 2 個誤解
✓
事實把『植物固醇』與『鋸棕櫚/南瓜籽油』混為一談，誤以為市售攝護腺複方的療效就是植物固醇單獨貢獻（實際多為複方且證據有限）
✓
事實誤以為攝護腺保健品（含植物固醇）能取代就醫與藥物治療，而非僅為輔助

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

複合植物固醇，含 β-穀固醇，113 毫克，180 片裝

代表來源 ↗
L10b · TFDA 法定身份 官方認定

得宣稱之保健功效共13項，包含「調節血脂」

來源 ↗

  • Alpha 阻斷劑
  • 5-α 還原酶抑制劑
  • 經尿道攝護腺切除術等手術治療
✓ PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 4 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v10 engine_version: v1.0 claim_id: CLM-COND-bph-INT-phytosterols-001
查看 ClaimReview 結構化資料 (JSON-LD) 
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-bph-INT-phytosterols-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "植物固醇能改善良性攝護腺肥大",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 2,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟠 C 薄弱證據"
  }
}